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Abstract
Background: This study was designed to investigate the association of the 894G>T polymorphism
in the eNOS gene with risk of acute myocardial infarction (AMI), extent of coronary artery disease
(CAD) on coronary angiography, and in-hospital mortality after AMI.
Methods: We studied 1602 consecutive patients who were enrolled in the GEMIG study. The
control group was comprised by 727 individuals, who were randomly selected from the general
adult population.
Results: The prevalence of the Asp298 variant of eNOS was not found to be significantly and
independently associated with risk of AMI (RR = 1.08, 95%CI = 0.77–1.51, P = 0.663), extent of
CAD on angiography (OR = 1.18, 95%CI = 0.63–2.23, P = 0.605) and in-hospital mortality (RR =
1.08, 95%CI = 0.29–4.04, P = 0.908).
Conclusion: In contrast to previous reports, homozygosity for the Asp298 variant of the 894G>T
polymorphism in the eNOS gene was not found to be associated with risk of AMI, extent of CAD
and in-hospital mortality after AMI
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Background
A single base exchange (G894→T) in exon 7 of the human
endothelial nitric oxide synthase (eNOS) gene results in a
Glu→Asp substitution at residue 298 of the eNOS gene.
The functional significance of this single nucleotide poly-
morphism remains an issue of controversy since homozy-
gosity for the Asp298 variant has been related to reduced
enzyme activity [1] and basal NO production [2], possibly
due to increased susceptibility to proteolytic cleavage [3],
although more recent reports have convincingly demon-
strated that this preferential cleavage could be a method-
ological artifact [4,5].
In accordance to the hypothesis that this polymorphism
may have an unfavorable effect on NO bioavailability,
homozygosity for the Asp298 variant has been reported to
influence vascular coronary reactivity [6], responsiveness
to a-adrenergic stimulation [7], and event free survival in
patients with nonischemic cardiomyopathy [8]. Based on
these reports a number of association studies have posi-
tively associated the presence of the Asp298 variant with
risk of AMI [9,10], carotid atherosclerosis [11], early
atherogenesis [12], and coronary in-stent restenosis [13],
while several studies have found no evidence for an asso-
ciation between the 894G>T polymorphism and prema-
ture CAD [14-17].
Based on data derived from a multicentre genetic epide-
miological study, we examined the association of this
genetic variant of eNOS gene with risk of AMI in a rela-
tively homogeneous, in terms of ethnic and cultural back-
ground, low coronary risk, Caucasian population.
Methods
Patient population
The GEMIG study (Genetics and Epidemiology of acute
Myocardial Infarction in the Greek population) is a mul-
ticenter study designed to evaluate the genetic predisposi-
tion of AMI and prognosis after AMI in the Greek
population. A total of 1602 consecutive patients, admit-
ted in hospital with the diagnosis of AMI, who have been
successfully genotyped for the 894G>T polymorphism
were enrolled in the study. The control group consisted of
805 adults (aged > 30 years old) who were randomly
selected from the city records. Blood samples for genetic
analyses were obtained from 794 of the study partici-
pants. Thirty-two out of the 794 eligible subjects had clin-
ical or electrocardiographic evidence of a possible MI and
were not included in the control group. Out of the
remaining 762 subjects, 727 were successfully genotyped
for the 894G>T polymorphism. The study methodology,
participating centers, study investigators and findings
have been published in details elsewhere [18-20]. The sci-
entific committee of the study and the local ethics com-
mittees of all participating institutes approved the study
protocol. Prior to that the scientific and ethics committee
of the coordinating center (Cardiac department of Athens
University, Hippokration Hospital, Athens, Greece) had
approved the study protocol. The protocol of the study
affected neither the diagnostic procedures, nor the thera-
peutic interventions applied to the studied patients who
gave informed consent for their participation.
Special characteristics of the study population
The Greek population is a relatively homogeneous Cauca-
sian population in terms of ethnic and cultural back-
ground, which presents low ischemic heart disease
mortality rates and low incidence of CAD despite the rel-
atively high prevalence of major coronary risk factors. The
aforementioned characteristics have been verified in large
scale epidemiological studies in the general population
[21] and in patients with documented CAD [22].
DNA analysis
In order to investigate the 894G>T polymorphism of
eNOS gene, located in exon 7, oligonucleotide primers for
polymerase chain reaction (PCR) were designed using the
published sequence of the human eNOS (NOS 3) gene
(Genbank/EMBL L10693–L10709) [23]. A coding
sequence variant, a G→T substitution in exon 7 (at posi-
tion 894) in codon 298, alters the amino acid at this resi-
due from Glu to Asp. Genotyping of this polymorphism
was performed by PCR amplification of exon 7, with the
flanking intronic primers 5'-CAT-GAG-GCT-CAG-CCC-
CAG-AAC-3' (sense) and 5'-AGT CAA-TCC-CTT-TGG-
TGC-TCA-C-3' (antisense), followed by MboI restriction
endonuclease digestion for 16 hours at 37°C. Non-dena-
turing, 3% agarose gel electrophoresis, was used to iden-
tify a single PCR product of 206 bp. Cleavage of the
product into 119 bp and 87 bp fragments occurred in the
presence of a T at nucleotide 894. The latter corresponds
to Asp298, while no restriction digestion products were
obtained in the absence of T at the same residue.
Statistical analysis
Statistical analyses were performed with SPSS software
(version 13.0, Chicago, IL, U.S.A.). A P value on a 2-sided
test of 0.05 for group comparisons and 0.10 for interac-
tion tests was considered statistically significant. Chi-
square tests were used to compare genotype frequencies in
different groups. Multivariate logistic regression analysis,
with an allowance for age only, age and gender, or a group
of the major cardiovascular risk factors (age, gender,
hypercholesterolaemia, hypertension, diabetes mellitus,
smoking and family history for CAD), was used to explore
the impact of Asp298 variant on risk of AMI. Chi-square
analysis was used to test the assumption of Hardy-Wein-
berg equilibrium.BMC Medical Genetics 2008, 9:43 http://www.biomedcentral.com/1471-2350/9/43
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Results
The main baseline characteristics of the patients with AMI
(cases) and of the subjects from the general population
(controls) are presented in Table 1. The frequencies of the
studied genotypes of the eNOS gene are shown in Figure
1. The observed frequencies of the studied alleles were in
Hardy-Weinberg equilibrium in both cases (χ2 = 0.20, P >
0.1) and controls (χ2 = 1.65, P > 0.1).
The frequency of the Asp/Asp genotype was not found to
differ significantly between cases and controls in relation
to the major coronary risk factors (gender, smoking status,
diabetes mellitus, hypercholesterolemia, hypertension,
obesity and family history of CAD). Furthermore, the
average number of the aforementioned risk factors did not
differ significantly in carriers versus non-carriers of the
Asp/Asp genotype, in both cases (2.36 vs 2.32, P = 0.771)
and controls (1.60 vs 1.81, P = 0.137).
Homozygosity for the Asp allele and risk of AMI and in-
hospital mortality of AMI
The frequency of the mutated genotype (Asp/Asp) did not
differ significantly between cases and controls (11.2 vs
10.7%, P = NS). Similarly, the Glu/Asp (43.8 vs 40.9, P =
NS) and the Glu/Glu (43.8 vs 40.9, P = NS) genotypes did
not differ significantly between the study groups in uni-
variate analysis. In backward stepwise logistic regression
analysis with age, gender, smoking status, diabetes melli-
tus, hypercholesterolemia, hypertension, obesity and
family history of CAD included as covariates, the presence
of the Asp/Asp genotype was not found to be independ-
ently associated with AMI (RR = 1.08, 95%CI = 0.77–1.51,
P = 0.663) (Figure 1).
Unadjusted in-hospital mortality of carriers and of non-
carriers of the Asp/Asp genotype did not differ signifi-
cantly (7.8 vs 7.7%, P = 0.939). Possession of this geno-
type was also not significantly associated with in-hospital
mortality in multivariate analysis adjusted for age, gender,
diabetes mellitus, hypertension, smoking status, obesity,
anterior location of infarction, administration of throm-
bolysis, and echocardiographic left ventricular ejection
fraction (RR = 1.08, 95%CI = 0.29–4.04, P = 0.908) (Fig-
ure 1).
Homozygosity for the Asp298 allele in relation to the 
number of diseased vessels
Out of the studied AMI patients, 614 underwent coronary
angiography during the hospitalization period. The fre-
quencies of the Asp/Asp genotype in relation to the
number of diseased vessels were 13.3, 8.1, and 9.3% in
patients with one-, two-, and three-vessel disease, respec-
tively (P = 0.192). In multivariate analysis adjusted for
age, gender, diabetes mellitus, smoking status, hyperten-
sion, hypercholesterolemia, and obesity, the Asp/Asp var-
iant was not found to be independently associated with
Synopsis of the results of multivariate analyses Figure 1
Synopsis of the results of multivariate analyses. The 
relative risks and the corresponding 95% confidence intervals 
for AMI, in-hospital mortality and multivessel disease in rela-
tion to the presence of the mutated (Asp/Asp) genotype are 
shown. Detailed description of the variables included in each 
multivariate analysis is presented in the results section of the 
manuscript.
Table 1: Baseline characteristics of the study population
Cases* n = 1602 Controls† n = 727 P value
Age (years) 62 ± 13 58 ± 15 < 0.001
Male gender 79% (n = 1261) 43% (n = 314) < 0.001
Diabetes 29% (n = 459) 11% (n = 77) < 0.001
Cigarette smoking 64% (n = 1017) 33% (n = 242) < 0.001
Hypercholesterolaemia 50% (n = 800) 33% (n = 241) < 0.001
Hypertension 45% (n = 719) 32% (n = 230) < 0.001
Heredity for CAD‡ 26% (n = 412) 22% (n = 158) 0.040
*Cases = successfully genotyped patients with acute myocardial infarction
†Controls = successfully genotyped individuals from the general population without a history of myocardial infarction
‡CAD = coronary artery disease.BMC Medical Genetics 2008, 9:43 http://www.biomedcentral.com/1471-2350/9/43
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the number of diseased vessels on coronary angiography
(OR = 1.18, 95%CI = 0.63–2.23, P = 0.605) (Figure 1).
Discussion
In contrast to previous reports, our results derived from a
specifically designed, prospective, multicentre study do
not support the hypothesis that homozygosity for the
G894→T polymorphism, in eNOS gene is associated with
increased risk of AMI. Furthermore, we found no relation
of this polymorphism with angiographic extent of CAD
and in-hospital mortality after AMI.
Genetic association studies for ischemic heart disease and 
special characteristics of the present study
The extensive search for a genetic variant that would influ-
ence significantly coronary risk, independently of the
major coronary risk factors, has been a target of cardiovas-
cular research on genetic epidemiology during the last
decades. However, genetic association studies for athero-
sclerotic cardiovascular diseases have resulted in conflict-
ing, non-reproducible and rather disappointing results.
Furthermore, publication bias has contributed to the con-
tamination of literature with small association studies
reporting positive results. Thus, data from association
studies should be evaluated in the context of their major
methodological limitations. The chance of a false linkage
in association studies is high and the replication of find-
ings, even in the same population, has been limited. In
addition, highly selected or not representative groups of
cases and controls, retrospective design, lack of multivari-
ate analysis, and bias introduced by selection by death
have also contributed to the plethora of contradictory
results in the field [24,25]. In this study we enrolled a
large number of consecutive patients hospitalized for
AMI, aiming to avoid misclassification with subjects not
really suffering from CAD. The control group was ran-
domly selected from the general adult population
included in the city catalogues aiming to avoid selection
biases.
The role of the 894G>T polymorphism on the function of 
eNOS
Endothelial NOS regulates NO synthesis by the endothe-
lium which is demonstrated to exert a key role on coro-
nary vasodilatation, vascular smooth muscle cell growth,
endogenous antioxidant defense and platelet aggregation
[26]. Several studies have examined whether the 894G>T
polymorphism of the eNOS gene alters the functional
profile of the protein, trying to provide a pathophysiolog-
ical background which could support the clinical hypoth-
esis of association between this polymorphism and
several cardiovascular diseases. Initial studies demon-
strated that the Asp298-encoded eNOS enzyme is more
prone to proteolytic cleavage, resulting in reduced levels
of functional eNOS and thus to a diminished steady-state
eNOS activity [3]. However, it has been indicated that the
reported preferential cleavage of the Asp298 eNOS variant
is rather a methodological artifact attributed to nonspe-
cific acid hydrolysis during sample preparation [3,4],
while proper buffer selection and avoidance of acid con-
ditions completely prevent Asp-eNOS proteolysis [5].
Furthermore, Golser et al. [27] reported that Asp298 vari-
ant purified from a yeast expression system does not influ-
ence enzyme function and can not explain endothelial
dysfunction associated with this polymorphism, while
Dosenko et al. [28] demonstrated that eNOS activity in
isolated human platelets from 894T/T homozygotes was
not significantly lower than in normal homozygotes. Fur-
ther evidence supporting the lack of functional signifi-
cance of this single nucleotide polymorphism was derived
from the elegant study by McDonald et al. [5] who
showed that Glu→Asp substitution at position 298 of the
eNOS does not modulate either the subcellular localiza-
tion and interaction with modulatory proteins of the
enzyme or its activity in intact human endothelial cells.
This is also consistent with the spatial location of the posi-
tion 298 of the eNOS gene, which is situated externally,
far from the binding sites of eNOS regulatory proteins
[29,30], and thus this polymorphism is considered
unlikely to alter the functional properties of the enzyme to
a considerable extent. These data strongly doubt the func-
tional significance of this polymorphism and favor the
scenario that this eNOS variant might be an indirect
marker of genetic association with other disease-related
variants in either the eNOS gene or at other loci [5].
Association of 894G>T polymorphism with risk of CAD
A metaanalysis of case-control studies evaluating the
potential association between 894G>T eNOS polymor-
phism and the risk of CAD reached the conclusion that
homozygosity for eNOS Asp298 allele was associated
with a moderately, though significantly increased risk of
CAD [OR = 1.31;95%CI = 1.13–1.51] [31]. The reported
results are amenable to criticism due to the significant het-
erogeneity of the individual odds ratios incorporated in
the calculation of the summary odds ratio. After excluding
from the analysis the study with the most influential odds
ratio, the authors abrogated the methodological limita-
tion of heterogeneity, but the calculated risk of CAD was
largely blunted and bordered on significance (summary
OR = 1.17; 95%CI = 1.00–1.36; P = 0.05).
Antoniades et al. [10] in an elegantly designed study with
229 consecutive patients with premature AMI, demon-
strated that homozygosity for this polymorphism is asso-
ciated with a significantly increased risk for premature
AMI. Although discordant at a first glance with our results,
the conclusions of this study refer to a different, younger
than our patient population, where the relative contribu-BMC Medical Genetics 2008, 9:43 http://www.biomedcentral.com/1471-2350/9/43
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tion of the 894G>T polymorphism to the susceptibility
for AMI might be enhanced. Furthermore, the fairly large
patient population of our study renders our results less
prone to the caveat of sampling variability in case-control
studies.
A large scale study on 5061 individuals of Japanese origin
demonstrated no association of the 894G>T polymor-
phism with risk of AMI [15]. Spence et al. [16] using fam-
ily-based association tests specifically designed for the
study of the genetic basis of multifactorial diseases, found
no evidence that the 894G>T eNOS gene polymorphism
was related to the development of CAD in a total of 1023
Caucasian individuals.
In a recent study of 861 diabetic men no significant asso-
ciation was observed between 894G>T eNOS polymor-
phism and risk of CAD [17]. There is also discrepancy in
the literature regarding the association between the
894G>T polymorphism and premature CAD. Granath
and colleagues[14] studying 573 patients younger than 50
years reported the absence of association between
894G>T eNOS polymorphism and premature CAD, while
in a recent smaller trial the TT genotype was significantly
and independently associated with premature CAD [32].
Gardemann and colleagues [33] studied young individu-
als with high risk atherosclerotic profile and reported an
association between 894G>T eNOS polymorphism and
CAD in this cohort. To our knowledge, this study is one of
the largest specifically designed study conducted in a gen-
eral Caucasian population to test the possible association
of this polymorphism with risk of AMI. Our results have
not validated the association between G894→T polymor-
phism, in the eNOS gene and increased risk of AMI.
Extent of CAD and in-hospital mortality in relation to 
eNOS genotypes
We have found no association of the studied genotypes
with extent of CAD and in-hospital mortality. Gorchakova
et al, recently showed that carriers of the mutated geno-
type have an increased risk of death or MI within one year
after coronary artery stenting [34].
Study limitations
The main limitation of this study is the lack of data on
eNOS activity that might have enabled us to establish cor-
relations of the studied genotype with both the intermedi-
ate (NO levels) and final phenotype (AMI) of interest.
Conclusion
In conclusion, this relatively large scale study, devalues
the hypothesized association of the G894→T polymor-
phism in the eNOS gene with risk of AMI which had been
verified in a series of relatively small association studies.
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